These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36348577)

  • 1. Regional location of lymph node metastases predicts survival in patients with
    Wang ZP; Chen JR; Zhao JG; Zhu S; Zhang XM; Liang JY; He B; Ni YC; Sun GX; Shen PF; Zeng H
    Asian J Androl; 2023; 25(4):462-467. PubMed ID: 36348577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
    Heesterman BL; van der Poel HG; Schoots IG; Mehra N; Aben KKH
    BJU Int; 2022 Aug; 130(2):217-225. PubMed ID: 34741789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of non-regional lymph node metastases accurately revealed on
    Jiang Z; Fan J; Gan C; Dong X; Gao G; Wang Z; He D; Li L; Duan X; Wu K
    EJNMMI Res; 2023 Jul; 13(1):64. PubMed ID: 37410264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of nonregional lymph node metastasis as a prognostic factor in metastatic prostate cancer patients.
    Cho S; Kang SG; Tae BS; Cheon J
    Korean J Urol; 2012 Oct; 53(10):673-9. PubMed ID: 23136626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    Ali A; Hoyle A; Mistry H; Clarke NW
    BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.
    Wenzel M; Wagner N; Hoeh B; Siech C; Koll F; Cano Garcia C; Ahrens M; Tilki D; Steuber T; Graefen M; Banek S; Chun FKH; Mandel P
    Prostate; 2024 Oct; 84(14):1320-1328. PubMed ID: 38987984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
    Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.
    Tappero S; Piccinelli ML; Incesu RB; Cano Garcia C; Barletta F; Morra S; Scheipner L; Baudo A; Tian Z; Parodi S; Dell'Oglio P; de Cobelli O; Graefen M; Chun FKH; Briganti A; Longo N; Ahyai S; Carmignani L; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Apr; 22(2):47-55.e2. PubMed ID: 37690970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
    Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
    Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery on Metastatic Foci is a Better Strategy for Stage IV Breast Cancer Patients with only Nonregional Lymph Node Metastasis.
    Jiao Y; Guo X; Wu H; Lv Q
    Adv Ther; 2023 Jul; 40(7):3247-3262. PubMed ID: 37270436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
    Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
    Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of patients with prostate carcinoma presenting as nonregional lymph node metastases.
    Furuya Y; Akakura K; Akimoto S; Ito H
    Urol Int; 1998 Oct; 61(1):17-21. PubMed ID: 9792977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
    Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
    Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with De Novo Metastatic Prostate Cancer.
    Zhao J; Liu J; Sun G; Zhang M; Chen J; Shen P; Liu Z; Liao B; Zhang X; Gong J; Chen N; Zeng H;
    J Urol; 2019 Apr; 201(4):759-768. PubMed ID: 30652989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
    Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
    Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.